Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes.
Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has commercialised CEQUA (cyclosporine ophthalmic solution) 0.09% in the US.
French pharma company Servier has acquired cancer drug Pixuvri (pixantrone) from US-based CTI BioPharma for an undisclosed price in a move to strengthen its oncology portfolio.
Celltrion announced that it is launching Temixy in the US, which were approved in November by US Food and Drug Administration (FDA).
US-based Amgen has agreed to acquire Celgene’s psoriasis drug Otezla (apremilast) and certain related assets and liabilities for $13.4bn (£10.9bn) in cash.
Pfizer is set to invest an additional $500m (£411m) to build an advanced gene therapy manufacturing facility in Sanford, North Carolina, US.
German pharma giant Bayer has agreed to offload its animal health unit to Elanco Animal Health for $7.6bn (£6.27bn) in a stock-cum-cash deal, in a move to focus on its life sciences business.
Gilead Sciences Canada announced that effective July 31, the Ontario Drug Benefit Program will provide eligible patients with access to Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets, a once-daily single tablet and complete regimen for the treatment of HIV-1 infection in adults. Health Canada granted a Notice of Compliance for BIKTARVY in July 2018.
Alvogen announced that its subsidiary Lotus Pharmaceuticals has launched Vinorelbine 20, 30 and 80mg soft capsules in Europe.
Pfizer announced the closing of its joint venture (JV) with GlaxoSmithKline to combine the parties’ respective consumer healthcare businesses to create the world’s largest over-the-counter (OTC) business with robust iconic brands.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.